Mitochondrial & Longevity ·
MOTS-c has shown potential in counteracting muscle atrophy caused by glucocorticoids. This peptide, derived from mitochondrial DNA, is being studied for its protective effects on human skeletal muscle cells, particularly in the context of glucocorticoid-induced muscle wasting. The implications of these findings could significantly impact therapeutic strategies for muscle atrophy.
What this study examined
This study investigated the effects of mitochondrial-derived peptides (MDPs), specifically MOTS-c and S14G-humanin (HNG), on dexamethasone (DEXA)-induced muscle atrophy in human skeletal myotubes. Primary human myotubes were fully differentiated and then exposed to DEXA, both alone and in combination with either 10 μM HNG or 10 μM MOTS-c. The researchers measured myotube size and differentiation, as well as various molecular markers associated with muscle atrophy.
Why it matters for MOTS-c research
The findings from this study are significant as they highlight the potential of MOTS-c as a protective agent against muscle wasting caused by glucocorticoids. Given that glucocorticoids like DEXA are widely used in clinical settings for their anti-inflammatory properties, understanding how MOTS-c can mitigate their adverse effects on muscle health is crucial. This research adds to the growing body of evidence supporting the therapeutic applications of mitochondrial-derived peptides in muscle preservation.
Key findings
- DEXA exposure resulted in a significant decrease in myotube size and differentiation.
- MOTS-c co-treatment preserved myotube area and fusion index compared to DEXA alone.
- MOTS-c increased Akt phosphorylation, which is indicative of enhanced cell survival signaling.
- MOTS-c inhibited the upregulation of muscle ring finger protein 1 (MURF1) and muscle atrophy F-box (MAFbx), both associated with muscle degradation.
- HNG co-treatment also preserved myotube area but did not affect the fusion index or E3 ligase mRNA levels.
- Both peptides showed potential in blunting DEXA-induced STAT3 activation.
How MOTS-c works (background)
MOTS-c is a mitochondrial-derived peptide that plays a role in cellular metabolism and stress response. It is thought to exert its effects through various signaling pathways, including the activation of Akt, which promotes cell survival and growth. By enhancing Akt signaling, MOTS-c may counteract the detrimental effects of glucocorticoids on muscle cells. Additionally, its ability to inhibit markers of muscle atrophy, such as MURF1 and MAFbx, suggests a multifaceted mechanism of action that includes both metabolic regulation and direct inhibition of muscle degradation pathways. This peptide's role in modulating cellular stress responses positions it as a promising candidate for further research in muscle health and metabolic disorders.
Practical takeaways for researchers
Researchers focusing on muscle atrophy and mitochondrial function may find MOTS-c to be a valuable area of study. The evidence presented in this study suggests that MOTS-c can effectively counteract the muscle-wasting effects of glucocorticoids, opening avenues for therapeutic applications. Future research should aim to elucidate the precise mechanisms by which MOTS-c operates and explore its potential in clinical settings, particularly for patients undergoing glucocorticoid therapy. Additionally, understanding the synergistic effects of MOTS-c with other MDPs, such as HNG, could lead to more comprehensive treatment strategies for muscle preservation.
FAQ
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide that has been implicated in the regulation of metabolism and cellular stress responses.
How does MOTS-c affect muscle atrophy?
MOTS-c has been shown to mitigate muscle atrophy by preserving myotube size and differentiation while inhibiting markers associated with muscle degradation.
What are the potential therapeutic applications of MOTS-c?
Given its protective effects against glucocorticoid-induced muscle wasting, MOTS-c may have therapeutic applications in treating conditions that lead to muscle atrophy, particularly in patients requiring glucocorticoid therapy.
Source: PubMed · Physiol Rep · published 2026-02-01.